AR Asset Management Inc. Increases Stake in Johnson & Johnson (NYSE:JNJ)

AR Asset Management Inc. lifted its stake in shares of Johnson & Johnson (NYSE:JNJGet Rating) by 7.1% during the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 40,945 shares of the company’s stock after acquiring an additional 2,700 shares during the period. Johnson & Johnson accounts for about 2.0% of AR Asset Management Inc.’s investment portfolio, making the stock its 12th largest position. AR Asset Management Inc.’s holdings in Johnson & Johnson were worth $6,689,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other large investors have also modified their holdings of the stock. 1900 Wealth Management LLC lifted its holdings in shares of Johnson & Johnson by 2.5% during the 3rd quarter. 1900 Wealth Management LLC now owns 8,815 shares of the company’s stock worth $1,440,000 after acquiring an additional 216 shares during the period. TRU Independence Asset Management 2 LLC raised its holdings in Johnson & Johnson by 13.2% in the third quarter. TRU Independence Asset Management 2 LLC now owns 1,924 shares of the company’s stock valued at $315,000 after buying an additional 225 shares during the period. Graypoint LLC raised its holdings in Johnson & Johnson by 13.2% in the third quarter. Graypoint LLC now owns 14,391 shares of the company’s stock valued at $2,351,000 after buying an additional 1,680 shares during the period. Telos Capital Management Inc. raised its holdings in Johnson & Johnson by 5.6% in the third quarter. Telos Capital Management Inc. now owns 75,866 shares of the company’s stock valued at $12,393,000 after buying an additional 4,048 shares during the period. Finally, United Capital Management of KS Inc. raised its holdings in Johnson & Johnson by 0.6% in the third quarter. United Capital Management of KS Inc. now owns 24,835 shares of the company’s stock valued at $4,057,000 after buying an additional 147 shares during the period. 67.94% of the stock is currently owned by hedge funds and other institutional investors.

Johnson & Johnson Stock Down 0.5 %

JNJ stock opened at $168.74 on Friday. Johnson & Johnson has a twelve month low of $155.72 and a twelve month high of $186.69. The company has a current ratio of 1.43, a quick ratio of 1.18 and a debt-to-equity ratio of 0.37. The company has a market capitalization of $441.17 billion, a P/E ratio of 23.50, a PEG ratio of 3.28 and a beta of 0.56. The firm has a 50 day simple moving average of $176.14 and a 200-day simple moving average of $171.30.

Johnson & Johnson (NYSE:JNJGet Rating) last released its quarterly earnings data on Tuesday, October 18th. The company reported $2.55 EPS for the quarter, topping analysts’ consensus estimates of $2.49 by $0.06. The firm had revenue of $23.79 billion during the quarter, compared to the consensus estimate of $23.44 billion. Johnson & Johnson had a net margin of 19.95% and a return on equity of 35.37%. The firm’s revenue was up 1.9% on a year-over-year basis. During the same quarter in the previous year, the company posted $2.60 earnings per share. On average, equities research analysts predict that Johnson & Johnson will post 10.04 earnings per share for the current fiscal year.

Johnson & Johnson Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, March 7th. Shareholders of record on Tuesday, February 21st will be issued a $1.13 dividend. This represents a $4.52 dividend on an annualized basis and a yield of 2.68%. The ex-dividend date is Friday, February 17th. Johnson & Johnson’s dividend payout ratio is presently 62.95%.

Analysts Set New Price Targets

Several research analysts recently commented on JNJ shares. Citigroup raised their price target on shares of Johnson & Johnson from $198.00 to $205.00 and gave the company a “buy” rating in a report on Monday, December 12th. Bank of America cut their price target on shares of Johnson & Johnson from $185.00 to $178.00 and set a “neutral” rating on the stock in a report on Friday, October 14th. Sanford C. Bernstein lowered their price objective on shares of Johnson & Johnson from $194.00 to $190.00 in a research report on Wednesday, October 19th. SVB Leerink lowered their price objective on shares of Johnson & Johnson from $194.00 to $186.00 and set an “outperform” rating for the company in a research report on Friday. Finally, Barclays assumed coverage on shares of Johnson & Johnson in a research report on Monday, October 17th. They issued an “equal weight” rating and a $175.00 price objective for the company. Seven equities research analysts have rated the stock with a hold rating, five have issued a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and an average price target of $181.75.

Insiders Place Their Bets

In other Johnson & Johnson news, VP Peter Fasolo sold 29,275 shares of Johnson & Johnson stock in a transaction on Monday, October 24th. The shares were sold at an average price of $171.36, for a total value of $5,016,564.00. Following the completion of the transaction, the vice president now owns 114,676 shares of the company’s stock, valued at $19,650,879.36. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. In other Johnson & Johnson news, CFO Joseph J. Wolk sold 14,781 shares of the firm’s stock in a transaction on Tuesday, December 13th. The stock was sold at an average price of $179.60, for a total value of $2,654,667.60. Following the sale, the chief financial officer now directly owns 35,812 shares in the company, valued at $6,431,835.20. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, VP Peter Fasolo sold 29,275 shares of the firm’s stock in a transaction on Monday, October 24th. The shares were sold at an average price of $171.36, for a total value of $5,016,564.00. Following the completion of the sale, the vice president now owns 114,676 shares in the company, valued at $19,650,879.36. The disclosure for this sale can be found here. Insiders sold a total of 277,886 shares of company stock valued at $48,550,549 over the last 90 days. 0.35% of the stock is owned by company insiders.

About Johnson & Johnson

(Get Rating)

Johnson & Johnson is a holding company, which engages in the research and development, manufacture and sale of products in the health care field. It operates through the following segments: Consumer Health, Pharmaceutical, and Medical Devices. The Consumer Health segment includes products used in the baby care, oral care, beauty, over-the-counter pharmaceutical, women’s health, and wound care markets.

Recommended Stories

Institutional Ownership by Quarter for Johnson & Johnson (NYSE:JNJ)

Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.